FLGT vs. GTH, FTRE, VCYT, CDNA, VRDN, CSTL, CELC, SERA, BDSX, and BNR
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Genetron (GTH), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), Castle Biosciences (CSTL), Celcuity (CELC), Sera Prognostics (SERA), Biodesix (BDSX), and Burning Rock Biotech (BNR).
Genetron (NASDAQ:GTH) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Genetron has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Genetron has a net margin of 0.00% compared to Genetron's net margin of -57.72%. Fulgent Genetics' return on equity of 0.00% beat Genetron's return on equity.
Fulgent Genetics has a consensus target price of $30.00, suggesting a potential upside of 40.52%. Given Genetron's higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Genetron.
Genetron has higher earnings, but lower revenue than Fulgent Genetics.
Fulgent Genetics received 242 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 60.70% of users gave Fulgent Genetics an outperform vote while only 33.33% of users gave Genetron an outperform vote.
10.7% of Genetron shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Fulgent Genetics had 3 more articles in the media than Genetron. MarketBeat recorded 3 mentions for Fulgent Genetics and 0 mentions for Genetron. Genetron's average media sentiment score of 1.25 beat Fulgent Genetics' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the news media.
Summary
Fulgent Genetics beats Genetron on 10 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fulgent Genetics Competitors List
Related Companies and Tools